Impact News +++ Blue Moon Metals Announces Key Strategic Appointments (PR Newswire) +++ BLUE MOON METALS Aktie -3,61%

CARDIOL Aktie

>CARDIOL Aktienkurs

1.166 EUR (TradegateBSX)

Ask: 1.178 EUR / 834 Stück

Bid: 1.154 EUR / 868 Stück

Tagesumsatz: 0 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

CARDIOL Aktie über LYNX handeln

Intraday

1 Jahr

>CARDIOL Performance

1 Woche: +4,7%

1 Monat: -0,7%

3 Monate: +30,5%

6 Monate: +29,4%

1 Jahr: +15,0%

laufendes Jahr: +36,8%

>CARDIOL Aktie

Name:

CARDIOL THERAPEUTICS CL.A

Land:

Kanada

Sektor:

Gesundheit

ISIN/ Wkn:

CA14161Y2006 / A2PA9E

Symbol/ Ticker:

CT9 (Frankfurt)

Kürzel:

FRA:CT9, ETR:CT9, CT9:GR

Index:

Webseite:

https://www.cardiolrx.com..

Profil:

Cardiol Therapeutics Inc. is a clinical-stage biotechnology company that focuses on developing innovative therapies for heart diseases. The company's primary objective is to research and produce anti-inflammatory and anti-fibrotic treatments aimed at..
>Volltext..

Marktkapitalisierung:

130.3 Mio. EUR

Unternehmenswert:

113.15 Mio. EUR

Umsatz:

EBITDA:

-21.79 Mio. EUR

Nettogewinn:

-22.32 Mio. EUR

Gewinn je Aktie:

-0.24 EUR

Schulden:

0.07 Mio. EUR

Liquide Mittel:

16.99 Mio. EUR

Operativer Cashflow:

Bargeldquote:

3.88

Umsatzwachstum:

Gewinnwachstum:

1.59%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

CARDIOL

Letzte Datenerhebung:

15.05.26

>CARDIOL Kennzahlen

Aktien/ Unternehmen:

Aktien: 111.87 Mio. St.

Frei handelbar: 96.94%

Leerverk. Aktien: -

Rückkaufquote: -13.76%

Mitarbeiter: 23

Umsatz/Mitarb.: -

Analysten:

Analystenrating: Strong buy

Kursziel: 413.53%

Bewertung:

KGV: -

KGV lG: -

KUV: -

KBV: 8.48

PEG-Ratio: -

EV/EBITDA: -

Rentabilität:

Bruttomarge: -

Gewinnmarge: -

Operative Marge: -

Managementeffizenz:

Gesamtkaprendite: -127.85%

Eigenkaprendite: -173.96%

>CARDIOL Peer Group

Gesundheit, Cannabis- Produkte, Herz-Kreislauf- Behandlung/ Kardiologie

>CARDIOL Chart & Kurs - Tradegate

>CARDIOL News

14.05.26 - 13:30	Cardiol Therapeutics to Participate in Fireside Chat at H.C. Wainwright 4th Annual BioConnect Investor Conference at the NASDAQ (PR Newswire)
	TORONTO, May 14, 2026 /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, is pleased to announce that it will participate in a......

07.05.26 - 13:31	Cardiol Therapeutics′ Phase II MAvERIC Results Accepted for Publication in the Journal of the American Heart Association (PR Newswire)
	Results demonstrate CardiolRx™ may represent a paradigm shift in the treatment of patients with recurrent pericarditis and further validate the ongoing Phase III trial, which recently surpassed 75% enrollment. TORONTO, ON, May 7, 2026 /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ:......

28.04.26 - 13:30	Cardiol Therapeutics Expands U.S. MAVERIC Phase III Trial Network to Address Growing Interest in the Pivotal Program (PR Newswire)
	Leading enrolling centers include Cleveland Clinic, three major campuses of the Mayo Clinic, Northwestern University, Massachusetts General Hospital, Columbia University–NewYork-Presbyterian, NYU Langone Health, Lenox Hill Hospital/Northwell Health, and Houston Methodist Hospital. Growing......

14.04.26 - 13:42	Cardiol Therapeutics Inc.: Cardiol Therapeutics to Highlight MAVERIC Phase III Trial and Recently Published ARCHER Results in Live Interview with Barchart (Newsfile)
	Toronto, Ontario--(Newsfile Corp. - April 14, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the......

01.04.26 - 13:42	Cardiol Therapeutics Inc.: Cardiol Therapeutics Announces Year-End 2025 Update on Operations (Newsfile)
	Initiated pivotal Phase III MAVERIC trial of CardiolRx in recurrent pericarditis and surpassed 50% patient enrollment, with full enrollment expected in Q2 2026.Reported positive Phase II ARCHER da......

25.02.26 - 13:49	Cardiol Therapeutics Inc.: Cardiol Therapeutics to Present at TD Cowen 46th Annual Health Care Conference (Newsfile)
	Toronto, Ontario--(Newsfile Corp. - February 25, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing ......

23.01.26 - 15:30	Cardiol Therapeutics Inc.: Cardiol Therapeutics Announces Closing of Bought Deal Financing and Full Exercise of Over-Allotment Option for Gross Proceeds of $14.85 Million (Newsfile)
	Toronto, Ontario--(Newsfile Corp. - January 23, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing t......

16.01.26 - 15:27	XFRA: CT9: Wiederaufnahme/Resumption (XETRA)
	FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE. THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE: INSTRUMENT NAME KUERZEL/SHORTCODE ISIN CARDIOL THERAPEUTICS CL.A CT9 CA14161Y2006 AB/FROM ONWARDS 16.01.2026 15:13 CET...

16.01.26 - 15:03	XFRA: CT9: Aussetzung/Suspension (XETRA)
	DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT: THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT: INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL CARDIOL THERAPEUTICS CL.A CT9 CA14161Y2006 BAW/UFN...

16.01.26 - 15:03	Cardiol Therapeutics announces $13.5M bought-deal private placement (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

16.01.26 - 14:54	Cardiol Therapeutics Inc.: Cardiol Therapeutics Announces Bought Deal Financing for Gross Proceeds of $13.5 Million (Newsfile)
	Toronto, Ontario--(Newsfile Corp. - January 16, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing t......

16.01.26 - 14:54	Cardiol Therapeutics Inc.: Cardiol Therapeutics Inc. Announces Bought Deal Financing for Gross Proceeds of $13.5 Million (Newsfile)
	Toronto, Ontario--(Newsfile Corp. - January 16, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing t......

16.01.26 - 14:48	XFRA: INSTRUMENT_SUSPENSION - CA14161Y2006 (XETRA)
	Instrument ID [6186088] (CT9 - CA14161Y2006) suspended...

13.01.26 - 13:42	Cardiol Therapeutics Inc.: Cardiol Therapeutics Achieves Key 50% Patient Enrollment Milestone in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis (Newsfile)
	Clinical trial infrastructure fully operational in the U.S. with more than 15 leading cardiovascular centers actively enrolling patients.Activation of additional top-tier clinical sites in Europe ......

01.12.25 - 13:42	Cardiol Therapeutics Inc.: New Data from the Phase II ARCHER Trial Demonstrate CardiolRx Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions (Newsfile)
	Phase II ARCHER trial showed a significant reduction in left ventricular (LV) mass (p=0.0117) and improvements in multiple key cardiac MRI (CMR) measures of structural heart recovery in patients w......

13.11.25 - 13:54	Cardiol Therapeutics Inc.: Cardiol Therapeutics Receives U.S. Patent Allowance Broadly Protecting its Heart Drugs to Late 2040 (Newsfile)
	Once issued, this new U.S. patent covers the use of CardiolRx and CRD-38 for a broad range of cardiac disorders, including atherosclerosis and heart failure, significantly expanding intellectual p......

05.11.25 - 14:01	Cardiol Therapeutics Inc.: Cardiol Therapeutics′ Phase II ARCHER Trial Results to be Presented at the European Society of Cardiology Scientific Meeting on Myocardial & Pericardial Diseases (Newsfile)
	The ESC M&PD meeting brings together the world's experts working to improve the treatment of myocarditis and pericarditis.Presentation to provide comprehensive findings from the ARCHER trial follo......

21.10.25 - 13:48	Cardiol Therapeutics Inc.: Cardiol Therapeutics Completes US$11.4 Million Financing and Extends Cash Runway into Q3 2027 (Newsfile)
	MAVERIC Phase III pivotal trial of orphan drug candidate CardiolRx in recurrent pericarditis is fully funded through to a planned New Drug Application submission with the FDA.New data from the ARC......

20.10.25 - 14:25	XFRA: CT9: Wiederaufnahme/Resumption (XETRA)
	FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE. THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE: INSTRUMENT NAME KUERZEL/SHORTCODE ISIN CARDIOL THERAPEUTICS CL.A CT9 CA14161Y2006 AB/FROM ONWARDS 20.10.2025 14:14 CET...

20.10.25 - 08:42	XFRA: CT9: Aussetzung/Suspension (XETRA)
	DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT: THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT: INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL CARDIOL THERAPEUTICS CL.A CT9 CA14161Y2006 BAW/UFN...

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Schlagworte sind Kommandos der Dummheit. - Hans Lohberger

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram